← Back to Search

Monoclonal Antibodies

Epratuzumab for Non-Hodgkin's Lymphoma

Phase 3
Waitlist Available
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 and over
Performance status: Karnofsky 60-100% or ECOG 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test the effectiveness of epratuzumab in treating low-grade non-Hodgkin's lymphoma that has not responded to chemotherapy or rituximab.

Who is the study for?
This trial is for adults with low-grade follicular B-cell non-Hodgkin's lymphoma that hasn't improved after chemotherapy or rituximab. Participants must have a measurable lesion and no bulky disease, serious conditions, other cancers in the past 5 years (except certain skin cancers or cervical carcinoma in situ), or current infections. They should not be pregnant, must test negative for pregnancy, use effective contraception during and post-trial, and have had no more than four prior treatments.Check my eligibility
What is being tested?
The trial is testing epratuzumab's effectiveness on patients with low-grade non-Hodgkin's lymphoma that didn't respond to previous treatments. Epratuzumab is a monoclonal antibody designed to target and kill tumor cells without harming normal cells. This phase III study aims to see if it can help where other therapies haven't.See study design
What are the potential side effects?
Epratuzumab may cause side effects similar to those of other monoclonal antibodies which include allergic reactions at the infusion site, fever, chills, nausea, fatigue, headache, rash and potential harm to normal cells leading to various organ-related symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I can care for myself and perform daily activities.
Select...
My liver tests are within the required limits.
Select...
My kidney function is normal or slightly above normal, unless due to my lymphoma.
Select...
My cancer is of the small cleaved or mixed cell type.
Select...
My blood counts meet the required levels and I don't need blood transfusions.
Select...
I have been diagnosed with a type of slow-growing lymphoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,646 Total Patients Enrolled
1,376 Trials studying Lymphoma
381,584 Patients Enrolled for Lymphoma
Jonsson Comprehensive Cancer CenterLead Sponsor
358 Previous Clinical Trials
26,076 Total Patients Enrolled
27 Trials studying Lymphoma
400 Patients Enrolled for Lymphoma
Peter J. Rosen, MDStudy ChairJonsson Comprehensive Cancer Center

Media Library

Epratuzumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00022685 — Phase 3
Lymphoma Research Study Groups:
Lymphoma Clinical Trial 2023: Epratuzumab Highlights & Side Effects. Trial Name: NCT00022685 — Phase 3
Epratuzumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00022685 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this treatment more harmful than other available options?

"There is some evidence to support the efficacy of this treatment, as it has advanced to a Phase 3 clinical trial. Furthermore, multiple rounds of data have confirmed its safety, so it received a score of 3."

Answered by AI

Are there any vacant positions in this trial for new participants?

"According to the latest information on clinicaltrials.gov, this particular clinical trial is not looking for any more participants. The study was originally posted on 2001-09-01 and was last updated on 2013-12-18. There are, however, 1,782 other clinical trials that are currently seeking candidates."

Answered by AI
~15 spots leftby Mar 2025